Designing a Phase 1 Single-Ascending-Dose Study of a Subcutaneous TACI-Fc Fusion Protein in Healthy Adults: Starting-Dose Derivation, Safety Gating, and Protocol Synopsis

A biologic that suppresses immunoglobulins and B cells for months asks a healthy volunteer to carry a risk with no personal benefit, so every element of a first-in-human design must be justified against that fact. This article develops a hypothetical Phase 1 single-ascending-dose study of a subcutaneous TACI-Fc fusion protein that neutralizes the cytokines BAFF and APRIL, intended for later development in a B-cell-driven kidney disease. It derives a 2 mg starting dose from assumed toxicology and pharmacologically active dose benchmarks, sets six planned dose cohorts and one optional cohort from 2 to 600 mg, and gates each escalation by sentinel dosing, a Safety Review Committee, an exposure cap, and immunoglobulin-based stopping rules. The synopsis specifies 48 randomized participants (up to 56), a 113-day follow-up with extension for persistent suppression, a pharmacokinetic and pharmacodynamic sampling plan, and a descriptive statistical analysis that includes a dose-proportionality criterion. Every nonclinical value is an explicit planning assumption, and the arithmetic is shown so that real data can replace it.Keywords: first-in-human; fusion protein; BAFF; APRIL; healthy volunteers; ICH S6(R1); sentinel dosing; minimal anticipated biological effect level

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426235
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a Phase 1 Single-Ascending-Dose Study of a Subcutaneous TACI-Fc Fusion Protein in Healthy Adults: Starting-Dose Derivation, Safety Gating, and Protocol Synopsis

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe et al.
Zenodo (CERN European Organization for Nuclear Research)
Statistical Methods in Clinical Trials
article

Designing a Phase 1 Single-Ascending-Dose Study of a Subcutaneous TACI-Fc Fusion Protein in Healthy Adults: Starting-Dose Derivation, Safety Gating, and Protocol Synopsis

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe, Precious Chinenye Sunday
article en

Abstract

A biologic that suppresses immunoglobulins and B cells for months asks a healthy volunteer to carry a risk with no personal benefit, so every element of a first-in-human design must be justified against that fact. This article develops a hypothetical Phase 1 single-ascending-dose study of a subcutaneous TACI-Fc fusion protein that neutralizes the cytokines BAFF and APRIL, intended for later development in a B-cell-driven kidney disease. It derives a 2 mg starting dose from assumed toxicology and pharmacologically active dose benchmarks, sets six planned dose cohorts and one optional cohort from 2 to 600 mg, and gates each escalation by sentinel dosing, a Safety Review Committee, an exposure cap, and immunoglobulin-based stopping rules. The synopsis specifies 48 randomized participants (up to 56), a 113-day follow-up with extension for persistent suppression, a pharmacokinetic and pharmacodynamic sampling plan, and a descriptive statistical analysis that includes a dose-proportionality criterion. Every nonclinical value is an explicit planning assumption, and the arithmetic is shown so that real data can replace it.Keywords: first-in-human; fusion protein; BAFF; APRIL; healthy volunteers; ICH S6(R1); sentinel dosing; minimal anticipated biological effect level

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Designing a Phase 1 Single-Ascending-Dose Study of a Subcutaneous TACI-Fc Fusion Protein in Healthy Adults: Starting-Dose Derivation, Safety Gating, and Protocol Synopsis — Peivand Pirouzi, Perpetua Ulofu, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS